|
市場調査レポート
商品コード
1292518
筋骨格系障害治療薬の世界市場規模、シェア、産業動向分析レポート:流通チャネル別、投与経路別、薬剤タイプ別、地域別展望と予測、2023年~2029年Global Musculoskeletal Disorders Drugs Market Size, Share & Industry Trends Analysis Report By Distribution Channel, By Route of Administration, By Drug Type, By Regional Outlook and Forecast, 2023 - 2029 |
||||||
|
筋骨格系障害治療薬の世界市場規模、シェア、産業動向分析レポート:流通チャネル別、投与経路別、薬剤タイプ別、地域別展望と予測、2023年~2029年 |
出版日: 2023年05月31日
発行: KBV Research
ページ情報: 英文 226 Pages
納期: 即納可能
![]() |
筋骨格系障害治療薬の市場規模は、2029年までに1,094億米ドルに達し、予測期間中に4.2%のCAGRで成長すると予測されています。
カーディナルマトリックスに掲載されている分析によると、ジョンソン・エンド・ジョンソン、ノバルティスAG、ファイザーが本市場の先行者となっています。2022年3月、ファイザーはアメリカのバイオ医薬品会社であるArena Pharmaceuticalsの買収を完了しました。この買収により、アリーナ・ファーマシューティカルズの素晴らしいパイプラインと経験をファイザーの免疫学と腫脹治癒領域に付加し、免疫炎症性疾患の患者さんの生活を変えるための前進の後押しのさらなる動機付けを支援することを目的としています。AbbVie, Inc.、Amgen, Inc.、UCB S.A.などの企業が、この市場における主要なイノベーターとして挙げられます。
COVID-19の影響分析
COVID-19のパンデミックは、飲食品、ヘルスケア、産業など、いくつかのエンドユーザー産業においてサプライチェーンの混乱を引き起こしました。また、COVID-19に端を発した景気後退により、筋骨格系疾患治療薬の市場も落ち込みました。COVID-19の大流行によりサプライチェーンが寸断され、臨床試験や医薬品開発が遅れたため、運動器疾患治療薬の市場に大きな影響を与えました。鎮痛剤を含む運動器障害治療薬の売上減少により、運動器障害治療薬の市場は期間中に縮小しました。しかし、市場の回復が予測され、筋骨格系疾患治療薬市場は今後も安定した成長が続くと予想されます。
市場の成長要因
筋骨格系疾患は極めて一般的
筋骨格系の障害として分類される疾患や状態は150以上あります。これらの障害は、筋肉、骨、関節、および隣接する結合組織の機能障害を特徴とします。これらの機能障害は、一時的または永続的な機能制限や関与の制限をもたらす可能性があります。WHOによると、全世界で17億1,000万人が、関節リウマチ、変形性関節症、腰痛、首の違和感、骨折、その他の怪我などの筋骨格系疾患に苦しんでいます。筋骨格系疾患はあらゆる年齢層の人々を悩ませていますが、その有病率は年齢や診断によって異なっています。筋骨格系疾患の患者数が増加すれば、その治療薬に対するニーズも高まり、市場拡大が加速されるものと思われます。
アルコール消費量の増加
個人レベルでも社会レベルでも、アルコール消費のレベル、パターン、集団におけるアルコール関連問題の範囲に影響を与える多くの変数が見つかっています。貧しい文化圏では、裕福な文化圏よりも、あるレベルやパターンの飲酒がもたらす健康への悪影響や社会的影響がより大きくなります。世界のアルコール関連による死亡者数のうち、男性が7.7%を占めるのに対し、女性は2.6%です。また、男性の飲酒者は2016年に1人当たり平均19.4リットルの純アルコールを使用しているのに対し、女性の飲酒者は平均7.0リットルを消費しています。関節疾患の発生率の高さとアルコール使用量の多さには関連性があるため、予測期間を通じてアルコール消費量の増加による市場の開拓が予想されます。
市場抑制要因
ヘルスケア専門家の不足
2035年には、1,290万人のヘルスケア専門家が不足すると予測されており、現在の720万人から増加すると考えられています。WHOが発表した最新の調査によると、医療従事者の不足は、迅速な対応がなされない場合、世界中の何十億人もの人々の健康に大きな影響を与える可能性があることが確認されています。この現象の要因として、労働力の高齢化が挙げられ、退職やより高給なポジションへの転職があっても、それに対応できる人材がいないことが挙げられます。また、新規参入者の不足、業界における不十分なトレーニングもあります。世界のさまざまな地域におけるヘルスケア人材の不足は、筋骨格系障害などの疾患の特定と管理に悪影響を及ぼし、関連する薬剤の必要性を減らし、市場拡大の妨げとなります。
薬剤タイプの展望
薬剤の種類により、市場は鎮痛剤、DMARDs、コルチコステロイド、その他に分類されます。2022年には、鎮痛剤セグメントが最大の収益シェアを獲得し、市場を独占しました。これは、鎮痛剤の価格が手ごろであるため、筋骨格系障害の治療薬として市場での需要が高まっているためです。さらに、鎮痛剤には中程度から強力なものまでさまざまな強さがあり、これらの多くは地元のドラッグストアや食料品店で市販されています。このように、OTCとして手頃な価格で入手できることが、このセグメントの拡大を後押しすると予想されます。
投与経路の展望
投与経路によって、市場は経口剤と非経口剤に分けられます。2022年の市場では、経口剤が大きな売上シェアを占めています。これは、多くの患者が他の治療法よりも経口薬を選択するという事実に起因しており、その理由は、経口薬は投与が容易で費用がかからないからです。多くの利点があるため、経口投与ルートは、多くの代替的な薬物送達方法よりも好まれています。その利点とは、異なる種類の薬剤に対応できる信頼性、安全性、優れた患者コンプライアンス、摂取の簡便性、痛みの回避、多用途性などです。経口投与に関連する利点は、市場セグメントの拡大の原動力となるでしょう。
流通経路の展望
流通チャネル別では、病院薬局、オンラインプロバイダー、ドラッグストア・小売薬局に分類されます。ドラッグストア&小売薬局セグメントは、2022年の市場において最大の収益シェアを示しました。これは、関節リウマチなどの筋骨格系の病気に苦しむ患者数が増加し、ドラッグストア&小売薬局における医薬品の需要が高まっているためです。また、これらの店舗では、顧客の合併症に対して、より個別的な解決策を提供することができ、患者は即座に薬を手にすることができるのです。医薬品を簡単に入手できることなどが、このセグメントの成長を高めると予想されます。
地域別の展望
地域別では、北米、欧州、アジア太平洋、LAMEAで市場を分析しています。北米地域は、2022年の市場において最も高い収益シェアを登録しました。この市場は、多数の主要企業の存在と、同地域の筋骨格系障害に対する医薬品生産の改善により拡大しています。さらに、強固なヘルスケアインフラ、大きな購買力、筋骨格障害用の鎮痛剤およびその他の医薬品の採用率の増加により、市場の発展が見込まれています。さらに、肥満、座りがちなライフスタイル、労働災害など、いくつかの原因による筋骨格系疾患の有病率の増加が、これらの症状を治療するための医薬品の需要増につながり、この地域の市場成長を後押ししています。
List of Figures
The Global Musculoskeletal Disorders Drugs Market size is expected to reach $109.4 billion by 2029, rising at a market growth of 4.2% CAGR during the forecast period.
Asia Pacific is one of the major contributors of the market as China, Japan, and India have aged population, thus capturing approximately 2/5th share of the market by 2029. For instance, over 60% of Japan's population is aged 30 and above. By 2050, most of the global population aged 60 and above is projected to be in low- and middle-income nations. The rise in life expectancy has led to a growing aging population. This emerging trend is advantageous for the market as it leads to a rise in the incidence of musculoskeletal diseases due to the illness's high prevalence in old adults and boosts the demand for its treatments, resulting in market expansion.
The major strategies followed by the market participants are Partnerships as the key developmental strategy to keep pace with the changing demands of end users. For instance, In January, 2022, The Johnson & Johnson Medical Devices Companies collaborated with Microsoft for expanding its digital surgery ecosystem. In addition, Pfizer came into collaboration with Sirana Pharma focusing on investigating treatment for a rare bone disease, through leveraging Sirana's microRNA targeting approach.
Based on the Analysis presented in the Cardinal matrix; Johnson & Johnson, Novartis AG, and Pfizer, Inc. are the forerunners in the Market. In March, 2022, Pfizer completed the acquisition of Arena Pharmaceuticals, an American biopharmaceutical company. Through this acquisition, the company aimed to adjoin the amazing pipeline and experience of Arena Pharmaceuticals to Pfizer's Immunology and swelling healing area, assisting further motive of advancement boost to change the lives of patients with the immuno-inflammatory illness. Companies such as AbbVie, Inc., Amgen, Inc., and UCB S.A. are some of the key innovators in Market.
COVID-19 Impact Analysis
The COVID-19 pandemic caused supply chain disruptions in several end-user industries, including food and beverage, healthcare, and industrial. In addition, the COVID-19-led economic slowdown resulted in a drop in the market for musculoskeletal disorders drugs. Since the COVID-19 pandemic disrupted supply chains and slowed down clinical studies and drug development, it had a considerable effect on the market for medications for musculoskeletal problems. Due to a drop in sales of medications for musculoskeletal disorders, including analgesics, the market for musculoskeletal disorders drugs shrank during the period. However, a rebound in the market is forecasted, and the musculoskeletal disease medications market is expected to continue growing steadily in the years to come.
Market Growth Factors
Musculoskeletal diseases are extremely common
There are more than 150 diseases and conditions that are categorized as musculoskeletal impairments. These impairments are characterized by muscle, bone, joint, and adjacent connective tissue dysfunction. These dysfunctions can result in temporary or permanent restrictions on functioning and involvement. According to WHO, 1.71 billion individuals globally suffer from musculoskeletal diseases, such as rheumatoid arthritis, osteoarthritis, low back pain, neck discomfort, fractures, and other injuries. Musculoskeletal problems afflict people of all ages; however, the prevalence differs by age and diagnosis. As more people suffer from musculoskeletal problems, there will likely be a greater need for pharmaceuticals to treat them, accelerating market expansion.
Higher alcohol consumption
At both the individual and societal levels, numerous variables that influence alcohol consumption levels, patterns, and the scope of alcohol-related issues in populations have been found. Poorer cultures experience more negative health effects and social implications from drinking at a given level and pattern of drinking than wealthier ones. Men account for 7.7% of all fatalities globally from alcohol-related causes, compared to women, who account for 2.6% of all deaths. In addition, male drinkers used 19.4 liters of pure alcohol on average per person in 2016, whereas female drinkers consumed 7.0 liters on average. As there is a link between higher rates of joint diseases and greater alcohol use, the market is anticipated to develop as a result of rising alcohol consumption throughout the projected period.
Market Restraining Factors
Insufficient availability of healthcare professionals
Projected for 2035, a shortage of 12.9 million healthcare professionals is anticipated, representing an increase from the current 7.2 million deficit. As per the recent research published by WHO, it has been observed that the dearth of healthcare professionals can significantly impact the health of billions of individuals globally if prompt action is not taken. Factors contributing to this phenomenon include an aging workforce, resulting in retirements or departures for higher-paying positions without corresponding replacements. Also, there is a shortage of new entrants and inadequate training in the industry. Insufficient healthcare personnel in different regions of the world will negatively impact the identification and management of ailments such as musculoskeletal disorders, reducing the need for associated medications and hindering market expansion.
Drug Type Outlook
Based on drug type, the market is segmented into analgesics, DMARDs, corticosteroids and others. The analgesics segment dominated the market with maximum revenue share in 2022. This is due to the affordability of analgesics, which is increasing their demand in the market as medications for musculoskeletal disorders. Additionally, they come in a variety of strengths, from moderate to powerful, and many of these are available over the counter at the local drugstore or grocery store. Thus, their affordability and availability as OTC is expected to boost the segment's expansion.
Route of Administration Outlook
On the basis of route of administration, the market is divided into oral and parenteral. The oral segment procured a substantial revenue share in the market in 2022. This is owing to the fact many patients choose oral drugs over other kinds of treatment because they are easier to administer and less expensive. Due to its many benefits, the oral administration route is favored above the many alternative medication delivery methods. These benefits include dependability to accommodate different drug types, safety, excellent patient compliance, simplicity of intake, pain avoidance, and versatility. The benefits associated with the oral route will drive the market segment's expansion.
Distribution Channel Outlook
By distribution channel, the market is classified into hospital pharmacies, online providers and drug stores & retail pharmacies. The drug stores & retail pharmacies segment witnessed the largest revenue share in the market in 2022. This is due to a growth in the number of patients suffering from musculoskeletal ailments such as rheumatoid arthritis, which raises the demand for pharmaceuticals in drug stores and retail pharmacies. Also, these stores are able to provide a much more personalized solution to the customer's complication, and the patient can have their medication instantly. The easy availability of drugs, combined with other factors, is expected to increase the segment's growth.
Regional Outlook
Region-wise, the market is analyzed across North America, Europe, Asia Pacific, and LAMEA. The North America region registered the highest revenue share in the market in 2022. The market is expanding due to the presence of numerous key companies and improvements in the region's medicine production for musculoskeletal disorders. Additionally, the market is anticipated to develop due to a solid healthcare infrastructure, significant purchasing power, and an increased adoption rate of analgesics and other medications for musculoskeletal disorders. Additionally, there has been an increase in the prevalence of musculoskeletal illnesses due to several causes, such as obesity, sedentary lifestyles, and workplace injuries, which has led to a rise in the demand for medications to treat these conditions, propelling the market growth in the region.
The market research report covers the analysis of key stake holders of the market. Key companies profiled in the report include AbbVie, Inc., Amgen, Inc., Eli Lilly And Company, F. Hoffmann-La Roche Ltd., Johnson & Johnson, Merck & Co., Inc., Novartis AG, Pfizer, Inc., Teva Pharmaceutical Industries Ltd., and UCB S.A.
Recent Strategies Deployed in Musculoskeletal Disorders Drugs Market
Acquisitions and Mergers:
Mar-2022: Pfizer completed the acquisition of Arena Pharmaceuticals, an American biopharmaceutical company. Through this acquisition, the company aimed to adjoin the amazing pipeline and experience of Arena Pharmaceuticals to Pfizer's Immunology and swelling healing area, assisting further motive of advancement boost to change the lives of patients with the immuno-inflammatory illness.
Mar-2022: UCB took over Zogenix, a US-based developer of therapeutic solutions. The addition of Zogenix expands and reinforces the acquiring company's market presence and reinforces its sustainable patient value strategy.
Oct-2021: Amgen took over Teneobio, a clinical-stage biotechnology company. With this acquisition, the company aimed to leverage Teneobio's antibody platform to complement its prevailing capabilities. Moreover, the company also aimed to gain a diverse range of building blocks that can be created into new multispecific therapeutics.
Partnerships, Collaborations and Agreements:
Jun-2022: Pfizer came into collaboration with Sirana Pharma, a Germany-based developer of a biotechnology company. The collaboration involves investigating treatment for a rare bone disease, through leveraging Sirana's microRNA targeting approach.
Jan-2022: The Johnson & Johnson Medical Devices Companies collaborated with Microsoft, a US-based technology company. The collaboration involves expanding the medical devices company's digital surgery ecosystem.
Feb-2021: UCB extended its collaboration agreement with Microsoft, a US-based technology company. The agreement involves advancing drug discovery and development. The collaboration integrates Microsoft's cloud, AI, computational services, and UCS's drug discovery abilities, and aims at identifying more effective molecules.
Geographical Expansions:
Sep-2022: AbbVie expanded its already existing facility located in Cork. The expansion includes building a new manufacturing facility and bringing in new technologies.
Approvals and Trials:
Apr-2022: AbbVie received FDA clearance for its RINVOQ. RINVOQ is intended for the treatment of ankylosing spondylitis (AS) in adults. The recently approved drug delivers quick disease control. Further, the approval demonstrates the company's continued advancement towards achieving its mission to accelerate the standards of care in rheumatic diseases.
Market Segments covered in the Report:
By Distribution Channel
By Route of Administration
By Drug Type
By Geography
Companies Profiled
Unique Offerings from KBV Research